<DOC>
	<DOC>NCT01353690</DOC>
	<brief_summary>The aim of this clinical study is to investigate the safety and feasibility of Autologous Muscle-derived Cells (AMDC; a preparation of a patient's own cells) as a treatment for patients with advanced heart failure caused by ischemia.</brief_summary>
	<brief_title>Autologous Cell Therapy for Ischemic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>Age greater than 18 but less than 80 years Prior myocardial infarction Depressed left ventricular ejection fraction (LVEF) ≤ 35% NYHA functional classification of II to IV Not under stable optimal medical management Cardiac surgery or percutaneous coronary intervention within 3 months Occurrence of myocardial infarction (MI) within 6 months, in the case of first MI, or 3 months, in the case of any subsequent MI Prior cell, gene, or transmyocardial laser revascularization therapy Ventricular wall thickness in target region ≤ 5 mm Moderate to severe aortic valve stenosis or mechanical valve replacement Left ventricular aneurysm or thrombus Left ventricular dysfunction associated with a reversible cause Vascular disease preventing percutaneous vascular access History of myopathic disease History of neoplasia within 5 years, except for basal cell carcinoma Receiving or planning to receive anticancer medications Serum creatinine &gt; 3.0 mg/dl Pregnant, planning to become pregnant, or breastfeeding a child in the next 18 months Life expectancy of less than 1 year Morbid obesity (defined as BMI &gt; 35) History of bleeding diathesis or coagulopathy Positive for HIV, Hepatitis B, or Hepatitis C Known hypersensitivity or contraindication to study product or treatment procedure Enrolled in another research project at the time of enrollment Unable to provide informed consent Unable or unwilling to commit to the followup clinical procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Cell Therapy</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Autologous</keyword>
	<keyword>Muscle-derived Cell</keyword>
</DOC>